MasoudiRSharafiMPourazadiLDadashpour DavachiNAsadzadehNEsmaeilkhanianSet al
Everyone's Insulin has gotten more expensive, and they come under fire in the public eye, the Saxenda not being the blockbuster drug that expectations had trumpeted it up to be, plus this increasing pressure around Insulin, and I think a CEO change
& Levine, H
In our personalized programs, we look at the big picture
The key strength of this study is that our patient population and study design are representative of a real-world clinical setting, including patients with various baseline HbA 1C concentration, weight, and BMI values who are taking other concomitant antihyperglycemic medications and have a history of prior GLP-1 RA and/or insulin use
However, the Canadian study included only patients aged 65 years and older, and the other study was conducted in the United Kingdom